{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"The CDKN2A gene encodes two proteins, p16INK4A and p14ARF, that regulate the cell growth and survival. CDKN2A is altered by mutation and/or deletion in a broad range of solid and hematologic cancers.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":"LEVEL_Fda3",
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":"LEVEL_4",
  "hotspot":false,
  "lastUpdate":"02/15/2023",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "19260062"
      ]
    },
    "description":"The CDKN2A A60V mutation is located in the ankyrin repeats of the p16/INK4A protein. This mutation has been found as a germline variant in families with melanoma. Expression of this mutation in vitro and in fibroblast cells demonstrated that it is inactivating as measured by decreased binding to CDK4 and increased cell proliferation compared to wildtype (PMID: 19260062).",
    "knownEffect":"Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"A60V",
    "alterationType":null,
    "consequence":"missense_variant",
    "entrezGeneId":1029,
    "hgvs":null,
    "hugoSymbol":"CDKN2A",
    "id":null,
    "proteinEnd":60,
    "proteinStart":60,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "approvedIndications":[],
      "description":"Palbociclib, ribociclib, and abemaciclib are selective small molecule inhibitors of CDK4 and CDK6 (PMID: 25941111). In a retrospective study of patients with uterine leiomyosarcoma, a patient harboring a CDKN2A mutation experienced stable disease and significant symptom reduction upon treatment with palbociclib (PMID: 28283584). In vitro studies of cancer cell lines with CDKN2A loss demonstrated that they are sensitive to CDK4/6 inhibition as measured by growth arrest upon drug treatment (PMID: 29232554). In a panel of melanoma and estrogen receptor-positive breast cancer cell lines, CDKN2A loss was found among cells with the highest sensitivity to palbociclib (PMID: 19874578, 24495407).",
      "drugs":[
        {
          "drugName":"Palbociclib",
          "ncitCode":"C49176",
          "synonyms":[],
          "uuid":null
        }
      ],
      "fdaLevel":"LEVEL_Fda3",
      "level":"LEVEL_4",
      "levelAssociatedCancerType":{
        "children":{},
        "code":"",
        "color":"",
        "id":984,
        "level":-1,
        "mainType":{
          "id":null,
          "name":"All Solid Tumors",
          "tumorForm":"SOLID"
        },
        "name":"",
        "parent":null,
        "tissue":"",
        "tumorForm":"SOLID"
      },
      "levelExcludedCancerTypes":[],
      "pmids":[
        "19874578",
        "24495407",
        "25941111",
        "29232554",
        "28283584"
      ]
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "approvedIndications":[],
      "description":"Palbociclib, ribociclib, and abemaciclib are selective small molecule inhibitors of CDK4 and CDK6 (PMID: 25941111). In a retrospective study of patients with uterine leiomyosarcoma, a patient harboring a CDKN2A mutation experienced stable disease and significant symptom reduction upon treatment with palbociclib (PMID: 28283584). In vitro studies of cancer cell lines with CDKN2A loss demonstrated that they are sensitive to CDK4/6 inhibition as measured by growth arrest upon drug treatment (PMID: 29232554). In a panel of melanoma and estrogen receptor-positive breast cancer cell lines, CDKN2A loss was found among cells with the highest sensitivity to palbociclib (PMID: 19874578, 24495407).",
      "drugs":[
        {
          "drugName":"Ribociclib",
          "ncitCode":"C95701",
          "synonyms":[],
          "uuid":null
        }
      ],
      "fdaLevel":"LEVEL_Fda3",
      "level":"LEVEL_4",
      "levelAssociatedCancerType":{
        "children":{},
        "code":"",
        "color":"",
        "id":984,
        "level":-1,
        "mainType":{
          "id":null,
          "name":"All Solid Tumors",
          "tumorForm":"SOLID"
        },
        "name":"",
        "parent":null,
        "tissue":"",
        "tumorForm":"SOLID"
      },
      "levelExcludedCancerTypes":[],
      "pmids":[
        "19874578",
        "24495407",
        "25941111",
        "29232554",
        "28283584"
      ]
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "approvedIndications":[],
      "description":"Palbociclib, ribociclib, and abemaciclib are selective small molecule inhibitors of CDK4 and CDK6 (PMID: 25941111). In a retrospective study of patients with uterine leiomyosarcoma, a patient harboring a CDKN2A mutation experienced stable disease and significant symptom reduction upon treatment with palbociclib (PMID: 28283584). In vitro studies of cancer cell lines with CDKN2A loss demonstrated that they are sensitive to CDK4/6 inhibition as measured by growth arrest upon drug treatment (PMID: 29232554). In a panel of melanoma and estrogen receptor-positive breast cancer cell lines, CDKN2A loss was found among cells with the highest sensitivity to palbociclib (PMID: 19874578, 24495407).",
      "drugs":[
        {
          "drugName":"Abemaciclib",
          "ncitCode":"C97660",
          "synonyms":[],
          "uuid":null
        }
      ],
      "fdaLevel":"LEVEL_Fda3",
      "level":"LEVEL_4",
      "levelAssociatedCancerType":{
        "children":{},
        "code":"",
        "color":"",
        "id":984,
        "level":-1,
        "mainType":{
          "id":null,
          "name":"All Solid Tumors",
          "tumorForm":"SOLID"
        },
        "name":"",
        "parent":null,
        "tissue":"",
        "tumorForm":"SOLID"
      },
      "levelExcludedCancerTypes":[],
      "pmids":[
        "19874578",
        "24495407",
        "25941111",
        "29232554",
        "28283584"
      ]
    }
  ],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The CDKN2A A60V mutation is likely oncogenic.",
  "vus":false
}